KATELYN GILLESPIE: Open Payments
NPI 1073092334 · GAINESVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,060 in 96 payments from 36 companies in 2025. Trend: 2023 $2,955 · 2024 $2,596 · 2025 $2,060
Food & beverage: $2,060
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $305 |
| PFIZER INC. | 11 | $153 |
| GlaxoSmithKline, LLC. | 6 | $129 |
| Merck Sharp & Dohme LLC | 5 | $121 |
| Daiichi Sankyo Inc. | 5 | $113 |
| Janssen Biotech, Inc. | 4 | $99 |
| ABBVIE INC. | 4 | $91 |
| GENZYME CORPORATION | 2 | $74 |
| Stemline Therapeutics Inc. | 3 | $69 |
| Aveo Pharmaceuticals, Inc. | 3 | $58 |
Products named: Fabhalta, KISQALI, OJJAARA, SCEMBLIX, DATROWAY, KEYTRUDA, VENCLEXTA, Orserdu.
Industry payments across GA — which companies pay providers there.
